Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.42 |
| ▸ | JAK1 | P23458 | 4/20 | 0.42 |
| ▸ | TYK2 | P29597 | 4/20 | 0.42 |
| ▸ | JAK3 | P52333 | 4/20 | 0.42 |
| ▸ | IDH1 | O75874 | 3/20 | 0.32 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.31 |
| ▸ | AXL | P30530 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31423999 | 0.87 | JAK2 (0.37) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423959 | 0.86 | JAK2 (0.42) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423912 | 0.86 | JAK2 (0.37) | JAK2JAK1TYK2JAK3IDH1 | |
| SCHEMBL31423877 | 0.86 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423971 | 0.83 | JAK2 (0.40) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423884 | 0.80 | JAK2 (0.46) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423956 | 0.80 | JAK2 (0.46) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423873 | 0.80 | JAK2 (0.46) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423907 | 0.80 | JAK2 (0.37) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31423918 | 0.78 | JAK2 (0.41) | JAK2JAK1TYK2JAK3CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025054386-A1 | CDK2 INHIBITORS AND USES THEREOF | ODYSSEY THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |